Key result
Early cardiac amyloidosis diagnosis enables timely treatment with expanding pharmacotherapies to improve heart failure outcomes.
Why the study?
Cardiac amyloidosis is an underdiagnosed cause of heart failure with poor prognosis when diagnosis is delayed, and early recognition is critical for improved outcomes.
This review highlights the critical need for increased awareness and early screening of cardiac amyloidosis to leverage newly available pharmaceutical therapies and improve patient outcomes.
Supports early recognition of cardiac amyloidosis in heart failure; leaves open optimal diagnostic and therapeutic strategies in diverse settings.
Cardiac amyloidosis is an underdiagnosed cause of heart failure. It occurs secondary to the deposition of amyloid protein in the myocardium. The main types of cardiac amyloidosis include light chain cardiac amyloidosis (AL), hereditary (hATTR) amyloidosis, and wild type (wtATTR) amyloidosis. Prognosis is poor when diagnosis is delayed. Early recognition and diagnosis are critical for improved outcomes. Cardiac amyloidosis, previously with limited treatment options, now has multiple pharmaceutical therapeutic options available. Increasing awareness of amyloidosis among patients and clinicians alike may lead to increased screening and diagnosis with institution of medical therapy early in the disease course. Particular attention needs to be focused on high risk populations, the elderly and patients of African ancestry.
No takes yet. Share an insight, caveat, or question.
Egolum et al. (2019) conducted a review in Cardiac amyloidosis. Cardiac amyloidosis is an underdiagnosed cause of heart failure that now has multiple pharmaceutical therapeutic options available, making early recognition and diagnosis critical for improved outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: